Interim OS data favored nivolumab versus the placebo in the intention-to-treat analysis (hazard ratio [HR] 0.76, 95% CI 0.61–0.96) and tumor PD-L1 >1% populations (HR 0.56, 95% CI 0.36–0.86) [14,57,58]. The gene discussed is CD274; the disease is neoplasm.